Next Phase Newsletter

Founded in 2019, the Venture Capital firm a space technology and human longevity-focused VC based in New York, USA. The firm had its hard launch in December 2020 at TechCrunch Sessions. The firm invests in Pre-seed, Seed, Seed+ companies at $200K with a possible follow-on of $400K and Series A & B rounds at $800K with a potential $1.6M follow-on. The firm will consider opportunities primarily in the Americas, UK, and EU. Also, the firm actively supports companies by providing connections to human capital providers, governmental entities, and suitable investors to help founders grow their business.

The firm will look at a broad spectrum of products and services within space technology and human longevity. The partners had previously invested in 20+ early-stage technology companies/ funds with active private deal-flow in the verticals of space, healthcare, and robotics. The firm is investing in biomarkers, diagnostics, digital health, and therapeutics (RX and OTC), dealing with the hallmarks of aging on the longevity side of things.

The firm will invest in privately held companies only and will participate as a co-investor. The firm prefers to invest in companies with at least three founders and will not invest in sole founder companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm is founded in 2010 with headquarters in Silicon Valley. Over the past 9 years, the firm has invested over 160 startups in deep tech-focused areas such as SaaS, Biotech, AI chips, Fintech, Blockchain, and Semiconductors; with 4 unicorns in the firm’s portfolio. The firm recently closed its fourth fund, of $50M AUM, and is actively seeking investment opportunities across a wide range of industries. Within the Life Science area, the firm is interested in Therapeutics, Medical Devices, Digital Health, and Diagnostics. The fund will focus on investing in the US or companies who are interested in entering the US market. On average, the typical size of investment is $0.5 – 1M but the firm also has follow-up investment strategies. The firm seeks to invest in early-stage companies, which Seed to Pre-A round is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and digital healthcare companies. The firm is open to a wide range of technologies including novel techniques. Within Medtech, the firm is strongly interested in robotics, semiconductors, sensors, AI modeling diseases, and telemedicine. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA.

The firm has a preference for companies with a full-time founding team and was founded recently (no more than 10 years). The firm can act as either a lead investor or co-investor depends on applicable cases. If the firm acts as the lead investor, it will seek a board seat or an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A newly established venture capital firm based in the USA has just successfully closed the first round of their fund ($20M target), and made its first investment. The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medical technology and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical needs. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A private/family investment vehicle based in Silicon Valley, CA. The firm makes seed investments via an accelerator arm, and also has a stage-agnostic fund. Seed investments are typically $25,000-100,000, and the firm is capable of making larger investments via the fund. The firm also provides a three-month accelerator program, and works with partners in the healthcare industry to strategically invest in startups. The firm will consider investing in companies worldwide.

The firm is interested in investing in digital health and medical technology and invests in subsectors in which the firm and its industry partners can apply expertise; within medical devices, typically this means products that have a significant software component, including biosensors, wearables and health monitoring devices. Within digital health, the firm’s interests include the following areas: Care Management, Hospital Workflow, Diagnostics, A.I. & Big Data, Population Health, Patient Adherence, Telemedicine. The firm is interested in both consumer applications and enterprise software. The firm works with strategic partners (including major pharma companies and health systems) to identify focus areas for innovation.

The firm prefers to invest in companies with at least two co-founders, one with technical expertise and one with business expertise; for the accelerator program in particular, the firm prefers to work with companies that have a technical expert co-founder. In addition to due diligence on the management team and technology, the firm also considers a product’s potential market opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.